Which has better earnings & valuation, SNY or MRK?

Merck & Co., Inc. has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.24 $8.84B $1.91 23.92 Merck & Co., Inc. $65.01B 5.72 $18.25B $1.25 120.54

Is SNY or MRK more profitable?

Sanofi has a net margin of 8.66% compared to Merck & Co., Inc.'s net margin of 4.77%. Merck & Co., Inc.'s return on equity of 16.73% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Merck & Co., Inc. 4.77% 16.73% 6.13%

Which has stronger earnings & valuation, SNY or NVS?

Novartis has higher revenue and earnings than Sanofi. Novartis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.24 $8.84B $1.91 23.92 Novartis $54.53B 5.53 $13.98B $6.63 23.83

Is SNY or NVS more profitable?

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Novartis 23.29% 38.56% 14.47%

Which has preferable earnings & valuation, AZN or SNY?

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.40 $10.23B $6.69 24.91 Sanofi $49.35B 2.24 $8.84B $1.91 23.92

Is AZN or SNY more profitable?

Astrazeneca has a net margin of 17.02% compared to Sanofi's net margin of 8.66%. Astrazeneca's return on equity of 31.45% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Sanofi 8.66% 14.19% 7.95%

Which has preferable valuation and earnings, NVO or SNY?

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.48 $15.51B $4.09 11.47 Sanofi $49.35B 2.24 $8.84B $1.91 23.92

Is NVO or SNY more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Sanofi's net margin of 8.66%. Novo Nordisk A/S's return on equity of 61.20% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 35.36% 61.20% 21.49% Sanofi 8.66% 14.19% 7.95%

Which has better valuation and earnings, PFE or SNY?

Sanofi has lower revenue, but higher earnings than Pfizer. Sanofi is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.55 $7.77B $0.76 36.80 Sanofi $49.35B 2.24 $8.84B $1.91 23.92

Is PFE or SNY more profitable?

Sanofi has a net margin of 8.66% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% Sanofi 8.66% 14.19% 7.95%

Sanofi (SNY) Competitors

$45.69 -0.16 (-0.35%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$45.69 0.00 (0.00%)

As of 08/24/2026 07:17 PM Eastern

Compare

SNY vs. MRK, NVS, AZN, NVO, and PFE

Should you buy Sanofi stock or one of its competitors? Sanofi's main competitors and comparable companies include Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Sanofi compare to Merck & Co., Inc.?

Sanofi (NASDAQ:SNY) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Merck & Co., Inc. has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.24	$8.84B	$1.91	23.92
Merck & Co., Inc.	$65.01B	5.72	$18.25B	$1.25	120.54

Sanofi has a net margin of 8.66% compared to Merck & Co., Inc.'s net margin of 4.77%. Merck & Co., Inc.'s return on equity of 16.73% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Merck & Co., Inc.	4.77%	16.73%	6.13%

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.3%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Merck & Co., Inc. had 106 more articles in the media than Sanofi. MarketBeat recorded 106 mentions for Merck & Co., Inc. and 0 mentions for Sanofi. Sanofi's average media sentiment score of 1.02 beat Merck & Co., Inc.'s score of 0.68 indicating that Sanofi is being referred to more favorably in the media.

Company	Overall Sentiment
Sanofi	Positive
Merck & Co., Inc.	Positive

14.0% of Sanofi shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sanofi has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Sanofi currently has a consensus target price of $49.50, indicating a potential upside of 8.34%. Merck & Co., Inc. has a consensus target price of $144.10, indicating a potential downside of 4.36%. Given Sanofi's higher possible upside, research analysts plainly believe Sanofi is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
Merck & Co., Inc.	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65

Summary

Sanofi and Merck & Co., Inc. tied by winning 10 of the 20 factors compared between the two stocks.

How does Sanofi compare to Novartis?

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 46.5% of its earnings in the form of a dividend.

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Novartis	23.29%	38.56%	14.47%

Novartis has higher revenue and earnings than Sanofi. Novartis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.24	$8.84B	$1.91	23.92
Novartis	$54.53B	5.53	$13.98B	$6.63	23.83

Sanofi currently has a consensus target price of $49.50, indicating a potential upside of 8.34%. Novartis has a consensus target price of $141.20, indicating a potential downside of 10.63%. Given Sanofi's stronger consensus rating and higher possible upside, research analysts plainly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, Novartis had 9 more articles in the media than Sanofi. MarketBeat recorded 9 mentions for Novartis and 0 mentions for Sanofi. Sanofi's average media sentiment score of 1.02 beat Novartis' score of 0.49 indicating that Sanofi is being referred to more favorably in the media.

Company	Overall Sentiment
Sanofi	Positive
Novartis	Neutral

Summary

Novartis beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Sanofi compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.40	$10.23B	$6.69	24.91
Sanofi	$49.35B	2.24	$8.84B	$1.91	23.92

Astrazeneca has a net margin of 17.02% compared to Sanofi's net margin of 8.66%. Astrazeneca's return on equity of 31.45% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Sanofi	8.66%	14.19%	7.95%

In the previous week, Astrazeneca had 9 more articles in the media than Sanofi. MarketBeat recorded 9 mentions for Astrazeneca and 0 mentions for Sanofi. Sanofi's average media sentiment score of 1.02 beat Astrazeneca's score of 0.65 indicating that Sanofi is being referred to more favorably in the news media.

Company	Overall Sentiment
Astrazeneca	Positive
Sanofi	Positive

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Astrazeneca presently has a consensus price target of $206.67, suggesting a potential upside of 24.00%. Sanofi has a consensus price target of $49.50, suggesting a potential upside of 8.34%. Given Astrazeneca's stronger consensus rating and higher possible upside, research analysts plainly believe Astrazeneca is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Astrazeneca beats Sanofi on 14 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Novo Nordisk A/S presently has a consensus price target of $64.94, suggesting a potential upside of 38.37%. Sanofi has a consensus price target of $49.50, suggesting a potential upside of 8.34%. Given Novo Nordisk A/S's higher possible upside, research analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.7%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, Novo Nordisk A/S had 19 more articles in the media than Sanofi. MarketBeat recorded 19 mentions for Novo Nordisk A/S and 0 mentions for Sanofi. Sanofi's average media sentiment score of 1.02 beat Novo Nordisk A/S's score of 0.50 indicating that Sanofi is being referred to more favorably in the news media.

Company	Overall Sentiment
Novo Nordisk A/S	Neutral
Sanofi	Positive

Novo Nordisk A/S has a net margin of 35.36% compared to Sanofi's net margin of 8.66%. Novo Nordisk A/S's return on equity of 61.20% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Sanofi	8.66%	14.19%	7.95%

Novo Nordisk A/S has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.48	$15.51B	$4.09	11.47
Sanofi	$49.35B	2.24	$8.84B	$1.91	23.92

Summary

Novo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Sanofi compare to Pfizer?

Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Pfizer presently has a consensus target price of $28.28, indicating a potential upside of 1.11%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 8.34%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

68.4% of Pfizer shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 1.0% of Sanofi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Sanofi has lower revenue, but higher earnings than Pfizer. Sanofi is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.55	$7.77B	$0.76	36.80
Sanofi	$49.35B	2.24	$8.84B	$1.91	23.92

In the previous week, Pfizer had 94 more articles in the media than Sanofi. MarketBeat recorded 94 mentions for Pfizer and 0 mentions for Sanofi. Sanofi's average media sentiment score of 1.02 beat Pfizer's score of 0.94 indicating that Sanofi is being referred to more favorably in the news media.

Company	Overall Sentiment
Pfizer	Positive
Sanofi	Positive

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.1%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Sanofi has a net margin of 8.66% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Sanofi	8.66%	14.19%	7.95%

Summary

Pfizer and Sanofi tied by winning 10 of the 20 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNY vs. The Competition

Export

Metric	Sanofi	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$111.16B	$12.54B	$7.36B	$12.81B
Dividend Yield	3.85%	2.61%	2.53%	10.78%
P/E Ratio	23.92	780.42	270.56	24.05
Price / Sales	2.24	758.20	639.67	105.69
Price / Cash	6.49	15.47	29.03	36.89
Price / Book	1.37	10.42	11.18	6.40
Net Income	$8.84B	$2.79B	$3.46B	$347.95M
7 Day Performance	1.60%	1.80%	1.73%	1.49%
1 Month Performance	5.40%	4.70%	7.34%	5.15%
1 Year Performance	-8.86%	7.66%	26.12%	17.01%

Sanofi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNY Sanofi	2.9745 of 5 stars	$45.69 -0.3%	$49.50 +8.3%	-11.0%	$111.16B	$49.35B	23.92	74,846	Positive News
MRK Merck & Co., Inc.	4.2047 of 5 stars	$136.09 +0.2%	$135.50 -0.4%	+72.8%	$335.14B	$65.01B	108.87	75,000	Analyst Upgrade
NVS Novartis	3.0115 of 5 stars	$152.18 +0.9%	$141.20 -7.2%	+24.5%	$287.90B	$56.69B	22.95	75,267
AZN Astrazeneca	4.8566 of 5 stars	$156.93 +0.3%	$211.00 +34.5%	N/A	$242.64B	$58.74B	23.46	96,100	Analyst Forecast
NVO Novo Nordisk A/S	4.4771 of 5 stars	$44.89 -2.2%	$64.94 +44.7%	-17.5%	$204.90B	$46.80B	10.98	69,505	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNY) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Competitors

SNY vs. MRK, NVS, AZN, NVO, and PFE

How does Sanofi compare to Merck & Co., Inc.?

Summary

How does Sanofi compare to Novartis?

Summary

How does Sanofi compare to Astrazeneca?

Summary

How does Sanofi compare to Novo Nordisk A/S?

Summary

How does Sanofi compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNY vs. The Competition

Sanofi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanofi (SNY) Competitors

SNY vs. MRK, NVS, AZN, NVO, and PFE

How does Sanofi compare to Merck & Co., Inc.?

Which has better earnings & valuation, SNY or MRK?

Is SNY or MRK more profitable?

Is SNY or MRK a better dividend stock?

Does the media favor SNY or MRK?

Do insiders and institutionals have more ownership in SNY or MRK?

Which has more risk & volatility, SNY or MRK?

Do analysts rate SNY or MRK?

Summary

How does Sanofi compare to Novartis?

Which has more volatility & risk, SNY or NVS?

Do institutionals & insiders hold more shares of SNY or NVS?

Is SNY or NVS a better dividend stock?

Is SNY or NVS more profitable?

Which has stronger earnings & valuation, SNY or NVS?

Do analysts prefer SNY or NVS?

Does the media prefer SNY or NVS?

Summary

How does Sanofi compare to Astrazeneca?

Which has more volatility and risk, AZN or SNY?

Which has preferable earnings & valuation, AZN or SNY?

Is AZN or SNY more profitable?

Does the media prefer AZN or SNY?

Do institutionals and insiders believe in AZN or SNY?

Do analysts recommend AZN or SNY?

Is AZN or SNY a better dividend stock?

Summary

How does Sanofi compare to Novo Nordisk A/S?

Do insiders & institutionals believe in NVO or SNY?

Do analysts prefer NVO or SNY?

Is NVO or SNY a better dividend stock?

Does the media prefer NVO or SNY?

Is NVO or SNY more profitable?

Which has more risk and volatility, NVO or SNY?

Which has preferable valuation and earnings, NVO or SNY?

Summary

How does Sanofi compare to Pfizer?

Do analysts recommend PFE or SNY?

Do institutionals and insiders believe in PFE or SNY?

Which has more volatility & risk, PFE or SNY?

Which has better valuation and earnings, PFE or SNY?

Does the media refer more to PFE or SNY?

Is PFE or SNY a better dividend stock?

Is PFE or SNY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNY vs. The Competition

Sanofi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools